IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer
IMUNON, Inc. provides an update on its Phase 3 OVATION 3 trial of IMNN-001 for advanced ovarian cancer, highlighting rapid site activation and enrollment momentum surpassing forecasts. Supported by positive Phase 2 survival data and a well-tolerated safety profile, enrollment rates are approximately 0.5 patients per site per month, exceeding planni…